Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,311,679 | 942,842 | 755,127 | 724,531 | 587,276 |
| Marketable Securities | 248,930 | 194,864 | 318,683 | 567,006 | 426,599 |
| Receivables | 908,214 | 660,535 | 633,704 | 461,316 | 373,399 |
| Inventories | 1,298,883 | 1,232,653 | 1,107,183 | 894,083 | 776,669 |
| Other current assets | 185,784 | 201,533 | 141,391 | 104,521 | 110,442 |
| TOTAL | $3,953,490 | $3,232,427 | $2,956,088 | $2,751,457 | $2,274,385 |
| Non-Current Assets | |||||
| PPE Net | 952,508 | 1,043,041 | 1,066,133 | 1,073,366 | 1,035,461 |
| Investments And Advances | 492,242 | 521,238 | 611,135 | 333,835 | 507,793 |
| Intangibles | 410,036 | 451,477 | 490,900 | 534,768 | 584,851 |
| Other Non-Current Assets | 1,785,746 | 1,740,757 | 1,717,347 | 1,681,648 | 1,602,282 |
| TOTAL | $3,640,532 | $3,756,513 | $3,885,515 | $3,623,617 | $3,730,387 |
| Total Assets | $7,594,022 | $6,988,940 | $6,841,603 | $6,375,074 | $6,004,772 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 493,877 | N/A | N/A |
| Accounts payable and accrued liabilities | 759,031 | 606,988 | 683,147 | 588,884 | 546,497 |
| TOTAL | $759,031 | $606,988 | $1,177,024 | $588,884 | $546,497 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 747,992 | 723,962 | 713,030 | 1,183,034 | 1,192,606 |
| TOTAL | $747,992 | $723,962 | $713,030 | $1,183,034 | $1,192,606 |
| Total Liabilities | $1,507,023 | $1,330,950 | $1,890,054 | $1,771,918 | $1,739,103 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 192,323 | 190,777 | 188,676 | 186,529 | 184,032 |
| Common Shares | 192 | 191 | 189 | 186 | 184 |
| Retained earnings | 154,206 | -194,695 | -621,554 | -789,199 | -930,760 |
| Other shareholders' equity | -23,981 | 50,426 | -38,648 | -12,726 | 4,743 |
| TOTAL | $6,086,999 | $5,657,990 | $4,951,549 | $4,603,156 | $4,265,669 |
| Total Liabilities And Equity | $7,594,022 | $6,988,940 | $6,841,603 | $6,375,074 | $6,004,772 |